Supreme Court Keeps Telehealth Abortion Access Intact for Now

The Supreme Court’s 7-2 order on May 14, 2026, leaves telehealth distribution of mifepristone available while litigation continues, preserving a primary route to medication abortion for patients in states with bans. Medication abortions accounted for roughly two-thirds of all U.S. procedures in 2023, and telehealth prescriptions now exceed interstate travel for residents of restrictive states. The immediate result maintains the status quo set by prior FDA rules, yet the decision also surfaces deeper statutory questions that remain unresolved.

The Fifth Circuit had reinstated in-person dispensing requirements earlier in May, prompting the emergency stay. Court records show the per curiam majority extended an initial administrative hold without altering FDA regulations. Justices Clarence Thomas and Samuel Alito dissented. Thomas argued that the 1873 Comstock Act bars mailing any drug intended to produce abortion and described the applicants’ position as tied to a “criminal enterprise.” Alito characterized the overall approach as a “scheme” to circumvent the 2022 Dobbs ruling that returned regulatory authority to the states.

Advocates tracking the case note that enforcement of the Comstock Act could affect not only mifepristone but also related medical supplies. A 2022 Department of Justice memo concluded the statute does not reach shipments lacking clear intent for unlawful use, and the law has seen no enforcement for decades. Legal scholars continue to debate its constitutionality under modern First Amendment standards. Meanwhile, the FDA has opened a safety review of mifepristone despite more than twenty years of data showing serious adverse events below one percent—lower than risks associated with childbirth.

The new FDA commissioner, Kyle Diamantas, has signaled that the review will be a priority. Providers report that misoprostol alone remains an alternative, though regimens without mifepristone involve longer durations and increased side effects. Groups on both sides of the issue expect further challenges in lower courts and possible administrative actions after the 2026 midterms. The central tension now centers on whether existing federal statutes and agency processes will be used to narrow access that the current order has left in place.